(Q33446456)

26 July 2017

title

Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients (English)

1 reference

26 July 2017

0 references

Pseudomonas aeruginosa

0 references

1 reference

Verhagen C

1

1 reference

26 July 2017

de Pauw BE

2

1 reference

26 July 2017

Donnelly JP

3

1 reference

26 July 2017

Williams KJ

4

1 reference

26 July 2017

de Witte T

5

1 reference

26 July 2017

Janssen TH

6

1 reference

26 July 2017

publication date

1 September 1986

1 reference

26 July 2017

1 reference

26 July 2017

volume

13

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

125-131

1 reference

An evaluation of the activity of cephalosporins against Pseudomonas aeruginosa

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Ceftazidime as a single agent in the treatment of severe Pseudomonas aeruginosa infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Ceftazidime treatment in intensive care patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Ceftazidime in patients with pseudomonas infections

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Neutropenia, fever, and infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Approaching the controversies in antibacterial management of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Pseudomonas bacteremia in patients with malignant diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Ceftazidime as first-line therapy for fever in acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Cyclosporine Nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Antibiotics in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

New beta-lactam antibiotics in granulocytopenic patients. New options and new questions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Single-agent therapy for infections in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

Comparative toxicities of third-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2886%2992813-6

7 January 2021

10.1016/S0163-4453(86)92813-6

Identifiers

DOI

1 reference

26 July 2017

1 reference